Making medicines affordable for everyone across America


Research finds critical flaws in the standard cost-effectiveness math some insurers use to deny coverage for new medicines.

September 6, 2023 - Cost-effectiveness analysis (CEA) is commonly used to inform the assessment of value from new healthcare technologies. However, traditional CEA methods often fail to capture important components of social value for biopharmaceutical and other innovations.
Read the full report here.

Inventing new medicines is a long climb

Who creates new medicines? Publicly funded research creates the necessary "base camp" knowledge, but it takes teams of innovators working with the support of private funding to reach risky new summits and provide patients with new cures.

Learn how the IRA makes new small molecule R&D uninvestable for diseases of aging

to the detriment of patients, innovators, & society

Our Call to Action

Leading biopharma Innovators, investors, and patient groups urged congress to solve affordability for patients through insurance reform. More than 300 industry leaders share ideas on how to save all Americans money while preserving research and development. Caution that government price controls will cease biopharma investment and significantly reduce availability of new medicines. Read what more here.

Become a First Responder & Thought Partner

Sign up to receive action alerts.

Help protect access to lifesaving medicines & preserve innovation for those still waiting for a cure.

Learn more.
Our Videos & Animation
Explore NPLB's core principles, positions and plans to make medicines affordable for all Americans, encourage innovation, and ensure that patients are heard.

What we're tweeting (and retweeting)

Follow us @NPLB_org
Follow us @NPLB_org

What we're tweeting (and retweeting)

Our goals

Make sure that everyone in America has affordable healthcare they can actually use and guarantee that our country continues to invest in new medicines that will help patients now and in the future.

out-of-pocket costs

Expand insurance
to everyone

Ensure that all drugs go generic

All posts

ICER’s ‘updated’ methodology falls far short

ICER acknowledges that their math is flawed, but they don'y fix their mistakes.

New cost-effectiveness model aims to better capture value of medicines to society

updated methodology accounts for disease severity, loss of market exclusivity, and social value

Drugs extending my life, but Boston institute disagrees

I'm fighting ALS-and the Institute for Clinical and Economic Review (ICER)

NPLB Statement on ICER’s Flawed Value Assessment Framework

ICER math must be significantly updated to incorporate quantifiable patient & societal benefits

NPLB Submits Comments on Medicare Drug Price Negotiation Program to CMS

Read NPLB's proposed fixes for successful IRA implementation

NPLB Submits Small Biotech Exception Comments to CMS

IRA's time-limited small biotech "exception" will not work as intended

We're determined to help you get the care and medicines your doctors say you need.

We are dedicated to creating and maintaining patient access to affordable drugs by holding both insurance and pharmaceutical companies accountable for their policies and practices.

About us
All articles
Affordability and Innovation

We are championing new laws to get insurance companies to do away with copays and out-of-pocket expenses.

We are pushing for reforms to guarantee that drug companies let their drugs go generic when they're supposed to do so.

Who we are

Explore our cause

Help for patients

Don’t despair. There’s help for you: assistance with copays, deductibles and other expenses.

Our strategy

Coalition building. Raising awareness. Encouraging innovation. Changing perceptions and policy. Making medicines affordable.

Our presentations

Clear-cut ideas and solutions. The science, economics and policy of affordability and innovation.

Did you know?

Increasing out-of-pocket costs by just $10 per prescription causes a 33% rise in mortality because fewer patients take the drugs their doctors prescribe.

Source: National Bureau of Economic Research, involved